Healthcare
Live Price
Offline$0.814
+3.69% today
1Y Change
-57.14%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RedHill Biopharma Ltd. (RDHL) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.81 and down 57.1% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -96.4%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -96.4%, EPS +100.0%, free cash flow -3.0% with operating margin -109.5% and ROIC -118.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RDHL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDHL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RDHL Max Drawdown
-70.44%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RDHL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
Latest Revenue
—
Latest Net Income
—
Free Cash Flow
—
Revenue Growth
-96.4%
EPS Growth
+100.0%
Gross Margin
63.3%
Net Margin
-98.7%
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.